By  John McCamant for Moneyshow.com
The move away from opioids is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.
Pacira Pharmaceuticals (PCRX) has developed Exparel, which is just beginning to fill this important and very large void for non-opioid pain medication.
Paicra has begun an aggressive investment growth plan surrounding Exparel — the drug is in “re-launch†mode and Pacira now has the ability to reclaim the drug’s benefit up to 72-hours of post-operative pain control in its label.
Product discussions and follow-ups are occurring steadily at major meetings such as the American Academy of Orthopedic Surgeons, major orthopedic care providers at the American Society of Regional Anesthesia meeting.
…read more click here for full interview